Pharmacokinetics of rifapentine and isoniazid and NAT2 and SLCO1B1 polymorphisms in pediatric Thai patients with latent tuberculosis infection

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20190423002

Enrollment

Registered

2019-04-23

Start date

2019-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Thai patients with latent tuberculosis infection rifapentine&#44

Interventions

Body weight 10&#45

14 kg&#44

received once&#45

weekly of rifapentine 300 mg and isoniazid 25 mg/kg (2&#45

11 years) or 15 mg/kg (â‰¥12 years) (maximum&#44

900 mg) ,Body weight >14&#45

25 kg&#44

weekly of rifapentine 450 mg and isoniazid 25 mg/kg (2&#45

900 mg) ,Body weight >25&#45

32 kg&#44

weekly of rifapentine 600 mg and isoniazid 25 mg/kg (2&#45

900 mg) ,Body weight >32&#45

50 kg&#44

weekly of rifapentine 750 mg and isoniazid 25 mg/kg (2&#45

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: -Male or female aged 2-18 years -Newly diagnosed LTBI patientsÂ -Informed consent

Exclusion criteria

Exclusion criteria: -Body weight <10 kg -Acute hepatitis

Design outcomes

Primary

Measure	Time frame
mean Tmax, Cmax, AUC of rifapentine and isoniazid 0, 1, 2, 4, 6, 8, 12, and 24 hours HPLC, LCMS	—

Secondary

Measure	Time frame
genotype variants of NAT2 and SLCO1B1 predose (0 hour) Real-time PCR	—

Countries

Thailand

Contacts

Public ContactPajaree Chariyavilaskul

Chulalongkorn University

buaying846@gmail.com022564481

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026